liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Coagulation of whole blood ex vivo: role of tissue factor, factor XI and factor XII for platelet-dependent coagulation amplification
Linköping University, Department of Biomedicine and Surgery, Clinical Chemistry. Linköping University, Faculty of Health Sciences.ORCID iD: 0000-0002-1920-3962
Linköping University, Department of Biomedicine and Surgery, Clinical Chemistry. Linköping University, Faculty of Health Sciences.
(English)Manuscript (preprint) (Other academic)
Abstract [en]

Activated platelets play an important part both in the formation of the platelet plug aud as a catalytic surface for the plasma coagulation factors. We have earlier shown that activation of platelets in whole blood collected without anticoagulauts shortens the clotting time by approximately 50%. Here, we examine the involvement of TF, factor XII and factor XI in this platelet-dependent coagulation acceleration.

Addition of an antibody against tissue factor did not prolong the clotting times for blood samples with platelet activators such as TRAP-6 or a collagen related peptide (CRP), nor for samples with only buffer added. Addition of com trypsin inhibitor (CTI) to inhibit fXIIa prolonged the clotting times by 21% for samples with eRP added. In samples with only buffer or with TRAP-6, en prolonged the clotting times by around 50%. Simultaneous addition of en and anti-TF did not cause any fnrther prolongation.

Addition of a polyclonal antibody against factor XI caused a more marked prolongation of the clotting times, especially for TRAP-6 and buffer containing samples, but also for CRP.

Only small amounts of thrombin-anti-thrombin (TAT) complexes were found in fresh blood samples directly after blood sampling, same amounts as described for blood down directly into tubes with anticoagulants. We cannot exclude the possibility that these small amounts could activate factor XI on the platelet surface, but that cannot explain the shortened clotting times and increased amounts of TAT found in samples with CRP added. The nature of this platelet-dependent coagulation amplification will be addressed in coming studies.

National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-84568OAI: diva2:560303
Available from: 2012-10-12 Created: 2012-10-12 Last updated: 2015-03-13Bibliographically approved
In thesis
1. The role of platelets in whole blood coagulation
Open this publication in new window or tab >>The role of platelets in whole blood coagulation
2003 (English)Doctoral thesis, comprehensive summary (Other academic)
Abstract [en]

The body's first line of defence against bleeding is the platelets, small cell fragments with multiple roles in the coagulation process. The platelets are patrolling our blood vessels, looking for damage in the endothelial cell layer, to which they attach and transform, recruit more platelets and assemble the plasma coagulation proteases on their surfaces. Cleavage of the plasma coagulation factors then leads to the formation of a fibrin network sealing the damage.

This thesis present studies of the role of platelets in whole blood coagulation, using methods which enable studies in a whole blood environment, flow cytometry and free oscillation rheometry (FOR). FOR proved to be equivalent in accuracy to visual inspection in detecting clotting, but allowing for simultaneous analysis of a large number of blood samples. A flow cytometry method for measuring the contents and release capacity of platelet dense granules was also developed.

FOR was used to study platelets in coagulation. A quick removal of all blood cells was shown to be enough to keep the plasma anticoagulated. Activation of platelets by addition of collagen or a thrombin receptor agonist peptide (TRAP-6) shortened the whole blood clotting time, indicating the importance of platelets for the acceleration of coagulation. Inhibitors of the platelet fibrinogen receptor prevented clot retraction and prolonged the clotting time with TRAP-6. In collagen-stimulated samples, however, MK-852 accelerated clotting but delayed completion of clotting, while abciximab prolonged both clotting time and completion of clotting. Inhibitors to the platelet ADP receptors prolonged the clotting time, but did not affect the coagulum elasticity or the resistance against fibrinolysis. The same results were seen in a patient with a defective release of dense granule contents (which normally includes ADP). When comparing the platelet surface exposure of phosphatidylserine (PS) with the actual shortening of the clotting time, we found that despite the large decrease in clotting times seen with collagen or TRAP-6, only low numbers of PS-exposing platelets were detected. Induction of a similar PS exposure by the calcium ionophore A23187 could not decrease the clotting times to the same extent, indicating that PS exposure is only one of the mechanisms involved in platelet binding of plasma coagulation factors. Addition of annexin V, a substance that binds to PS, hampered, but could not abolish, coagulation. Artificial PS-containing lipid vesicles could not replace platelets, as they did not affect the coagulation of blood or plasma. To see which coagulation pathway that was involved in platelet dependent blood coagulation, inhibitors to factor XII or tissue factor (TF) were added to the blood prior to the platelet agonist Inhibition of factor xn increased the clotting time from about 10 to 15 minutes. Inhibition of TF was without effect. The results harmonised with the coagulation behaviour of blood congenitally deficient in factor XII or VII. Inhibition of factor XI caused a two to three fold increase in clotting time.

We conclude that plasma does not necessarily coagulate if all blood cells are quickly removed. Activated platelets accelerate the coagulation of native whole blood ex vivo in a process which is independent of TF. Platelet PS, factor XI and factor XII all promote this coagulation, but are not essential This suggests that there might exist a platelet dependent blood coagulation pathway differing from the established pathways. Drugs affecting the platelet fibrinogen and ADP receptors affect the coagulation of the blood samples which might be detected by FOR. Our studies suggest the possibility of using FOR to measure the "platelet reactivity potential".

Place, publisher, year, edition, pages
Linköping: Linköpings universitet, 2003. 86 p.
Linköping University Medical Dissertations, ISSN 0345-0082 ; 776
National Category
Medical and Health Sciences
urn:nbn:se:liu:diva-25703 (URN)10079 (Local ID)91-7373-535-3 (ISBN)10079 (Archive number)10079 (OAI)
Public defence
2003-03-14, Aulan, Administrationshuset, Hälsouniversitet, Linköping, 09:00 (Swedish)
Available from: 2009-10-08 Created: 2009-10-08 Last updated: 2015-03-13Bibliographically approved

Open Access in DiVA

No full text

Search in DiVA

By author/editor
Ramström, SofiaLindahl, Tomas L.
By organisation
Clinical ChemistryFaculty of Health Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 378 hits
ReferencesLink to record
Permanent link

Direct link